Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial

Hepatology

Volumn 24, Issue 5, 1996, Pages 1034-1040

  Lindsay, Karen L ^a,m   Davis, Gary L ^b   Schiff, Eugene R ^c   Bodenheimer, Henry C ^d   Balart, Luis A ^e   Dienstag, Jules L ^f,n   Perrillo, Robert P ^g   Tamburro, Carlo H ^h   Goff, John S ⁱ   Everson, Gregory T ⁱ   Silva, Marcelo ^c   Katkov, William N ^f   Goodman, Zachary ^j   Lau, Johnson Y N ^b   Maertens, Geert ^k   Gogate, Jagadish ^l   Sanghvi, Bharati ^l   Albrecht, Janice ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d BROWN UNIVERSITY   (United States)

^e OCHSNER MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h University of Louisville School of Medicine   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^k INNOGENETICS   (Belgium)

^l MERCK RESEARCH LABORATORIES   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; LEVOTHYROXINE; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2B INTERFERON; THYROTROPIN; VIRUS RNA;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOCRINE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEPATITIS C; HUMAN; INFLUENZA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 10344247665     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008903371     Document Type: Article

References (28)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer H, Perrillo R, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989; 321:1501-1506.
2. DiBisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-bind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
3. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A and non-B hepatitis. Gastroenterology 1991;101:497-502.
4. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, et al. Recombinant human alpha-interferon in patients with chronic non A non B hepatitis: a multicenter randomized controlled trial from France. HEPATOLOGY 1991;13:393-397.
5. Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L, Gallo V, Petrino R, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11(suppl 1): 43S-49S.
6. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991; 13:192-199.
7. Shindo M, Di Bisceglie AM, Cheung L, Shih W-K, Cristiano K, Feinstone H, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-704.
8. Davis GL, Lindsay K, Albrecht J, Bodenheimer HC, Balart LA, Perrillo RP, Dienstag JL, et al. Clinical predictors of response to recombinant alpha interferon treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). J Viral Hepat 1994;1:55-63.
9. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
10. Collins ML, Zayati C, Detmer JJ, Daly B, Kolberg JA, Cha TA, Irvine BD, et al. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem 1995;226: 120-129.
11. Lau JYN, Davis GL, Orita E, Qian KP, Mizokami M. Significance of antibody to the host cellular gene derived epitope GOR in chronic hepatitis C virus infection. J Hepatol 1993;17:253-257.
12. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74: 1093-1102.
13. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
14. Yousefi S, Escobar MR, Gouldin CW. A practical cytopathic effect/dye uptake interferon assay for routine use in the laboratory. Am J Clin Pathol 1985;83:735-740.
15. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C [editorial]. J Hepatol 1994;21:1-3.
16. Davis GL, Lau JYN, Lim H. Therapy for hepatitis C. Gastroenterol Clin North Am 1994;23:603-613.
17. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM, and Le Groupe Francais pour l'Etude du Traitement des Hepatites Chroniques NANB/C. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994;106:686-690.
18. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal R, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alfa 2b for 60 weeks. HEPATOLOGY 1994;19:280-285.
19. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. HEPATOLOGY 1995;21:291-297.
20. Lau JYN, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 1993;342:1208-1209.
21. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. Ann Intern Med 1995;122:586-591.
22. Saleh MG, Tibbs CJ, Koskinas J, Pereira LMMB, Bomford AB, Portmann BC, McFarlane IG, et al. Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. HEPATOLOGY 1994; 20:1399-1404.
23. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Pouliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. HEPATOLOGY 1995;22:1050-1056.
24. Lau JYN, Davis GL, Prescott LE, Maertens G, Lindsay KL, Qian K-P, Mizokami M, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med 1996;124:868-876.
25. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakash T, Yamamoto C, Ogura Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
26. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to alpha interferon therapy in chronic hepatitis C [editorial]. HEPATOLOGY 1995;22:1326-1329.
27. Lau JYN, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T, Perrillo RP, et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995;171:281-289.
28. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A non-B hepatitis. N Engl J Med 1995;332:1457-1462.